posted on 2020-05-28, 17:33authored byIuliia Polina, Mark Domondon, Rebecca Fox, Anastasia Sudarikova, Miguel Troncoso, Valeria Vasileva, Yuliia Kashyrina, Monika Gooz, Ryan Schibalski, Kristine Y. DeLeon-Pennell, Wayne R. Fitzgibbon, Daria IlatovskayaDaria Ilatovskaya
Supplementary Figure 1S. Body
weight before (normal salt) and on day 21 after a switch to a high salt (4% NaCl) diet, and heart to
body weight ratio (endpoint) in the experimental animals (Dahl SS rats) administered vehicle (veh), sacubtril/valsartan (sac/val), valsartan (val) and sacubitril only (sac).
Supplementary Figure 2S.Endpoint plasma electrolyte levels (Na+,
K+, Cl-) in the experimental groups (Dahl SS rats) administered vehicle (veh), sacubtril/valsartan (sac/val), valsartan (val) and sacubitril only (sac) for 21 days on a high salt diet (4% NaCl).
Funding
NIDDK R00 DK105160 (to DVI), Dialysis Clinic Inc Reserve Fund, MUSC SCTR support program via NIH/NCATS UL1TR001450 (DVI), the APS Research Career Enhancement, and Lazaro J Mandel awards to DVI. NIDA U54DA016511, the Biomedical Laboratory Research and Development Service of the VA Office of Research and Development Award IK2BX003922 and the APS 2019 S&R Foundation Ryuji Ueno Award (all to KYD-P). The Cell & Molecular Imaging Shared Resource, Hollings Cancer Center, Medical University of South Carolina P30 CA138313 (MG).